A study based on prostate, lung, colorectal and ovarian (PLCO) cancer screenings pointed that DRE trial with a normal PSA result led to an additional capture of 2% of men with clinically significant prostate cancer. This evidence concerns the gene KLK3 and Familial prostate cancer.